MEI Pharma Inc

For the period ended Jun 30, 2024. Filed Sep 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Sep 19, 2024

LITS$0.95-6.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except par value amounts)

	June 30,	June 30,
	2024	2023
ASSETS
Current assets:
Cash and cash equivalents	$3,705	$16,906
Short-term investments	34,640	83,787
Unbilled receivables	—	85
Prepaid expenses and other current assets	2,424	6,750
Total current assets	40,769	107,528
Operating lease right-of-use asset	214	11,972
Property and equipment, net	392	1,309
Total assets	$41,375	$120,809
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$3,168	$6,134
Accrued liabilities	5,187	12,461
Deferred revenue	—	317
Operating lease liability	—	1,428
Total current liabilities	8,355	20,340
Deferred revenue, long-term	—	64,545
Operating lease liability, long-term	—	11,300
Total liabilities	8,355	96,185
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding	—	—
Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at June 30, 2024 and June 30, 2023.	—	—
Additional paid-in capital	421,239	430,621
Accumulated deficit	(388,219)	(405,997)
Total stockholders’ equity	33,020	24,624
Total liabilities and stockholders’ equity	$41,375	$120,809

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.